Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on EOG Resources, Lowers Price Target to $121

Morgan Stanley maintains EOG Resources (NYSE:EOG) with a Equal-Weight and lowers the price target from $122 to $121.

byBenzinga Newsdesk

December 13, 2021

1 minute read

Morgan Stanley maintains EOG Resources (NYSE:EOG) with a Equal-Weight and lowers the price target from $122 to $121.

Recap: Fulcrum Therapeutics Q1 Earnings

By Benzinga Insights

Today, 2:37 AM

Fulcrum Therapeutics (NASDAQ:FULC) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

FULC

Cleveland Fed President Loretta Mester Says Makes Sense To Slow Down A Bit The Pace Of Rate Hikes; Can Now Be Very Deliberate In Setting Policy; Need To Be More Judicious In Balancing Risks; Not Anywhere Near To Stopping Rate Hikes Though

By Benzinga Newsdesk

Today, 2:37 AM

- CNBC Interview

SPY

News

Altair U.S. Intends To Reject Avalara Inc’s Proposed Sale To Vista Equity Partners

By Benzinga Newsdesk

Today, 2:37 AM

- Reuters

AVLR

Analyst Ratings

What 4 Analyst Ratings Have To Say About Solid Biosciences

By Benzinga Insights

Today, 2:37 AM

Over the past 3 months, 4 analysts have published their opinion on Solid Biosciences (NASDAQ:SLDB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

SLDB

Morgan Stanley Maintains Equal-Weight on EOG Resources, Lowers Price Target to $121

Related Posts

Recap: Fulcrum Therapeutics Q1 Earnings

Cleveland Fed President Loretta Mester Says Makes Sense To Slow Down A Bit The Pace Of Rate Hikes; Can Now Be Very Deliberate In Setting Policy; Need To Be More Judicious In Balancing Risks; Not Anywhere Near To Stopping Rate Hikes Though

Altair U.S. Intends To Reject Avalara Inc’s Proposed Sale To Vista Equity Partners

What 4 Analyst Ratings Have To Say About Solid Biosciences